TY - JOUR
T1 - Global epidemiology of hip fractures
T2 - A study protocol using a common analytical platform among multiple countries
AU - Sing, Chor Wing
AU - Lin, Tzu Chieh
AU - Bartholomew, Sharon
AU - Bell, J. Simon
AU - Bennett, Corina
AU - Beyene, Kebede
AU - Bosco-Lévy, Pauline
AU - Chan, Amy Hai Yan
AU - Chandran, Manju
AU - Cheung, Ching Lung
AU - Doyon, Caroline Y.
AU - Droz-Perroteau, Cécile
AU - Ganesan, Ganga
AU - Hartikainen, Sirpa
AU - Ilomaki, Jenni
AU - Jeong, Han Eol
AU - Kiel, Douglas P.
AU - Kubota, Kiyoshi
AU - Lai, Edward Chia Cheng
AU - Lange, Jeff
AU - Lewiecki, E. Michael
AU - Liu, Jiannong
AU - Man, Kenneth K.C.
AU - Mendes De Abreu, Mirhelen
AU - Moore, Nicolas
AU - O'Kelly, James
AU - Ooba, Nobuhiro
AU - Pedersen, Alma B.
AU - Prieto-Alhambra, Daniel
AU - Shin, Ju Young
AU - Sørensen, Henrik T.
AU - Tan, Kelvin Bryan
AU - Tolppanen, Anna Maija
AU - Verhamme, Katia M.C.
AU - Wang, Grace Hsin Min
AU - Watcharathanakij, Sawaeng
AU - Zhao, Hongxin
AU - Wong, Ian C.K.
N1 - Funding This work was supported by Amgen Inc. Award/Grant number is not applicable.
Publisher Copyright:
© Authors 2021
PY - 2021/7/28
Y1 - 2021/7/28
N2 - Introduction Hip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records. Methods and analysis This retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported. Ethics and dissemination Each participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences.
AB - Introduction Hip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records. Methods and analysis This retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported. Ethics and dissemination Each participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences.
UR - http://www.scopus.com/inward/record.url?scp=85111638010&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-047258
DO - 10.1136/bmjopen-2020-047258
M3 - Article
AN - SCOPUS:85111638010
SN - 2044-6055
VL - 11
JO - BMJ Open
JF - BMJ Open
IS - 7
M1 - e047258
ER -